Analysts positive on US prospects for tivozanib but data request weighs on Aveo stock
This article was originally published in Scrip
It's hard to say whether investors were reacting more to Aveo Oncology's larger net loss or news that the US FDA had asked for more data on overall survival rates versus Nexavar (sorafenib) for the US company's Phase III kidney cancer drug and lead product candidate tivozanib, but the firm's stock price fell 26.8% when it announced second quarter 2012 earnings on 2 August.
You may also be interested in...
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.